The pathogenesis of cancer metastasis: relevance to biotherapy

  • Robert Radinsky
  • Sharon L. Aukerman
  • Isaiah J. Fidler


Metastasis — the spread of malignant tumor cells from a primary neoplasm to distant parts of the body where they multiply to form new growths — is a major cause of death from cancer. The treatment of cancer poses a major problem to clinical oncologists, because by the time many cancers are diagnosed, metastasis may already have occurred, and the presence of multiple metastases makes complete eradication by surgery, radiation, drugs, or biotherapy nearly impossible (Table 1). Metastases can be located in different organs and in different locations within the same organ. These aspects significantly influence the response of tumor cells to therapy and the efficiency of anticancer drugs, which must be delivered to tumor foci in amounts sufficient to destroy cells without leading to undesirable side-effects. Similarly, immune effector cells of current biotherapeutic regimens may have difficulty reaching or localizing in some metastatic sites.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Albini A, Aukerman SL, Ogle RC et al. The in vitro invasiveness and interactions with laminin of K-1735 melanoma cells. Evidence for different laminin-binding affinities in high and low metastatic variants. Clin Exp Metastasis 1989; 7: 437–51PubMedGoogle Scholar
  2. 2.
    Arceci RJ, Croop JM, Horwitz SB, Housman D. The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. Proc Natl Acad Sci USA 1988; 85; 4350–4.PubMedGoogle Scholar
  3. 3.
    Arnold A, Staunton CE, Kim HG, Gaz RD, Kronenberg HM. Monoclonality and abnormal parathyroid hormone genes in parathyroid adenomas. N Engl J Med 1988; 318: 658–62.PubMedGoogle Scholar
  4. 4.
    Baselga J, Norton L, Masui H et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993; 85: 1327–33.PubMedGoogle Scholar
  5. 5.
    Baskin F, Rosenberg RN, Dev V. Correlation of double-minute chromosomes with unstable multidrug cross-resistance in uptake mutants of neuroblastoma cells. Proc Natl Acad Sci USA 1981; 78: 3654–8.PubMedGoogle Scholar
  6. 6.
    Basset P, Bellocq JP, Wolf C et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990; 348: 699–704.PubMedGoogle Scholar
  7. 7.
    Bellot F, Moolenaar W, Kris R et al. High-affinity epidermal growth factor binding is specifically reduced by a monoclonal antibody, and appears necessary for early responses. J Cell Biol 1990; 110: 491–502.PubMedGoogle Scholar
  8. 8.
    Benathan M, Frenk E. Melanocyte growth stimulation by lethally irradiated fibroblasts in vitro. J Invest Dermatol 1987; 89: 323.Google Scholar
  9. 9.
    Benathan M, Pararas C, Frenk E. Modulatory growth effects of 3T3 fibroblasts on cocultivated human melanoma cells. Anticancer Res 1991; 11: 203–8.PubMedGoogle Scholar
  10. 10.
    Berger MS, Greenfield C, Gullick WJ et al. Evaluation of epidermal growth factor receptors in bladder tumours. Br J Cancer 1987; 56: 533–7.PubMedCentralPubMedGoogle Scholar
  11. 11.
    Bigner SH, Humphrey PA, Wong AJ et al. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 1990; 50: 8017–22.PubMedGoogle Scholar
  12. 12.
    Biswas C. Collagenase stimulation in cocultures of human fibroblasts and human tumor cells. Cancer Lett 1984; 24: 201–7.PubMedGoogle Scholar
  13. 13.
    Bouziges F, Simo P, Simon-Assman P, Haffen K, Kedinger M. Altered deposition of basement-membrane molecules in co-cultures of colonic cancer cells and fibroblasts. Int J Cancer 1991; 48: 101–8.Google Scholar
  14. 14.
    Bradley G, Juranka PE, Ling V. Mechanism of multidrug resistance. Biochim Biophys Acta 1988; 948: 87–128.PubMedGoogle Scholar
  15. 15.
    Brattain MG, Brattain DE, Sarrif AM, McRae LJ, Fine WD, Hawkins JG. Enhancement of growth of human colon tumor cell lines by feeder layers of murine fibroblasts. J Natl Cancer Inst 1982; 69: 767–71.PubMedGoogle Scholar
  16. 16.
    Buchdunger E, Trinks U, Mett H et al. 4,5-Dianilinophtalimide: a protein-tyrosine kinase inhibitor with selectivity for the the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity. Proc Natl Acad Sci USA 1994; 91: 2334–8.PubMedGoogle Scholar
  17. 17.
    Buckley-Sturrock A, Woodward SC, Senior RM, Grimm GL, Klagsbrun M, Davidson JM. Differential stimulation of collagenase and chemotactic activity in fibroblasts derived from rat wound repair tissue and human skin by growth factors. J Cell Physiol 1989; 138: 70–8.PubMedGoogle Scholar
  18. 18.
    Camps JL, Chang SM, Hsu TC et al. Fibroblast-mediated acceleration of human epithelial tumor growth in vivo. Proc Natl Acad Sci USA 1990; 87: 75–9.PubMedGoogle Scholar
  19. 19.
    Cavanaugh PG, Nicolson GL. Purification and some properties of a lung-derived growth factor that differentially stimulates the growth of tumor cells metastatic to the lung. Cancer Res 1989; 49: 3928–33.PubMedGoogle Scholar
  20. 20.
    Chabner BA, Foji A. Multidrug resistance: P-glycoprotein and its allies–the elusive foes. J Natl Cancer Inst 1989; 81: 910–13.PubMedGoogle Scholar
  21. 21.
    Chackal-Roy M, Niemeyer C, Moore M, Zetter BR. Stimulation of human prostatic carcinoma cell growth by factors present in human bone marrow. J Clin Invest 1989; 84: 43–50.PubMedCentralPubMedGoogle Scholar
  22. 22.
    Chang I, Chung LWK. Interaction between prostatic fibroblast and epithelial cells in culture: role of androgen. Endocrinology 1989; 125: 2719–27.PubMedGoogle Scholar
  23. 23.
    Chew EC, Mok CH, Tsao SW, Liu WK, Riches DJ. Scanning electron microscopic study of invasiveness between normal and neoplastic cells and fibroblast in mono-layer culture. Anticancer Res 1988; 8: 275–80.PubMedGoogle Scholar
  24. 24.
    Chodak GW, Hospelhorn V, Judge SM, Mayforth R, Koeppen H, Sasse J. Increased levels of fibroblast growth factor-like activity in urine from patients with bladder or kidney cancer. Cancer Res 1988; 48: 2083–8.PubMedGoogle Scholar
  25. 25.
    Chua CC, Geiman DE, Keller GH, Ladda RL. Induction of collagenase secretion in human fibroblast cultures by growth promoting factors. J Biol Chem 1986; 260: 5213–16.Google Scholar
  26. 26.
    Chung LWK. Fibroblasts are critical determinants in pro-static cancer growth and dissemination. Cancer Metastasis Rev 1991; 10: 263–75.PubMedGoogle Scholar
  27. 27.
    Collard JG, Roos E, La Riviere G, Habets GGM. Genetic analysis of invasion and metastasis. Cancer Surveys 1988; 7: 691–710.PubMedGoogle Scholar
  28. 28.
    Cordon-Cardo C, O’Brien IP, Casals DD, Bertino JR, Melamed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990; 38: 1277–87.PubMedGoogle Scholar
  29. 29.
    Cornil I, Man MS, Fernandez B, Kerbel RS. Enhanced tumorigenicity, melanogenesis and metastasis of a human malignant melanoma observed after subdermal implantation in nude mice. J Natl Cancer Inst 1989; 81: 938–44.PubMedGoogle Scholar
  30. 30.
    Cornil I, Theodorescu D, Man S, Herlyn M, Jambmrosie J, Kerbel RS. Fibroblast cell interactions with human melanoma cells affecting tumor cell growth are a function of tumor progression. Proc Natl Acad Sci USA 1991; 88: 6028–32.PubMedGoogle Scholar
  31. 31.
    Croop JM, Gros P, Housman DE. Genetics of multidrug resistance. J Clin Invest 1988; 81: 1303–9.PubMedCentralPubMedGoogle Scholar
  32. 32.
    Croop JM, Raymond M, Haber D et al. The three mouse multidrug resistance (mdr)genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol 1989; 9: 1346–50.PubMedCentralPubMedGoogle Scholar
  33. 33.
    Crouch EC, Stone KR, Bloch M, McDivitt RW. Heterogeneity in the production of collagens and fibronectin by morphologically distinct clones of a human tumor cell line: evidence for intratumoral diversity in matrix protein biosynthesis. Cancer Res 1987; 47: 6086–92.PubMedGoogle Scholar
  34. Cunha GR, Chung LWK. Stromal-epithelial interaction. I. Induction of prostatic phenotype in urothelium of tesicular feminized (TFm/y)mice. J Steroid Biochem 1981; 14: 1317–21.Google Scholar
  35. 35.
    Dabbous MK, Walker R, Haney LM, Custer LM, Nicolson GL, Wooley DE. Mast cells and matrix degradation at sites of tumor invasion in rat mammary adenocarinoma. Br J Cancer 1986; 54: 459–65.PubMedCentralPubMedGoogle Scholar
  36. 36.
    Davey GC, Currie GA, Alexander P. Immunity as the predominant factor determining metastasis by murine lymphomas. Br J Cancer 1979; 40: 590–6.PubMedCentralPubMedGoogle Scholar
  37. 37.
    De Clerck YA. Purification and characterization of a collagenase inhibitor produced by bovine vascular smooth muscle cells. Arch Biochem Biophys 1988; 265: 28–37.Google Scholar
  38. 38.
    Deffie AM, Alam T, Seneviratne C et al. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia. Cancer Res 1988; 48: 3595–602.PubMedGoogle Scholar
  39. 39.
    Defize LHK, Boonstra J, Meisenhelder J et al. Signal transduction by epidermal growth factors occurs through the subclass of high affinity receptors. J Cell Biol 1990; 109: 2495–507.Google Scholar
  40. 40.
    Deuchars KL, Ling V. P-glycoprotein and multidrug resistance in cancer chemotherapy. Semin Oncol 1989; 16: 156–65.PubMedGoogle Scholar
  41. 41.
    Deuel TF. Polypeptide growth factors: roles in normal and abnormal cell growth. Annu Rev Cell Biol 1987; 3: 443–92.PubMedGoogle Scholar
  42. 42.
    Devault A, Gros P. Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol Cell Biol 1990; 10: 1652–63.PubMedCentralPubMedGoogle Scholar
  43. 43.
    Doerr R, Zvibel I, Chiuten D et al. Clonal growth of tumors on tissue-specific biomatrices and correlation with organ site specificity of metastases. Cancer Res 1989; 49: 384–92.PubMedGoogle Scholar
  44. 44.
    Dong Z, Radinsky R, Fan D et al. Organ-specific modulation of steady-state mdr gene expression and drug resistance in murine colon cancer cells. J Natl Cancer Inst 1994; 86: 913–20.PubMedGoogle Scholar
  45. 45.
    Ellis SM, Nabeshima K, Biswas C. Monoclonal antibody preparation and purification of a tumor cell collagenasestimulatory factor. Cancer Res 1989; 49: 3385–91.PubMedGoogle Scholar
  46. 46.
    Enami J, Enami S, Koga M. Growth of normal and neoplastic mouse mammary epithelial cells in primary culture: stimulation by conditioned medium from mouse mammary fibroblasts. Jpn J Cancer Res 1983; 74: 845–53.Google Scholar
  47. 47.
    Ervin PR, Kaminski MS, Cody RL, Wicha MS. Production of mammastatin, a tissue-specific growth inhibitor, by normal human mammary cells. Science 1989; 244: 1585–7.PubMedGoogle Scholar
  48. 48.
    Ewing J. Neoplastic Diseases, 2nd edn. Philadelphia: WB Saunders, 1928.Google Scholar
  49. 49.
    Ezekowitz RAB, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infance. N Engl J Med 1992; 326: 1456–63.PubMedGoogle Scholar
  50. 50.
    Fabra A, Nakajima M, Bucana CD, Fidler IJ. Modulation of the invasive phenotype of human colon carcinoma cells by fibroblasts from orthotopic or ectopic organs of nude mice. Differentiation 1992; 52: 101–10.PubMedGoogle Scholar
  51. 51.
    Failkow PJ. Clonal origin of human tumors. Annu Rev Med 1979; 30: 135–43.Google Scholar
  52. 52.
    Fan D, Chakrabarty S, Seid C et al. Clonal stimulation or inhibition of human colon carcinomas and human renal carcinoma mediated by transforming growth factor-ß1. Cancer Commun 1989; 1: 117–25.PubMedGoogle Scholar
  53. 53.
    Fan Z, Masui H, Altaws I, Mendelsohn J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1993; 53: 4322–8.PubMedGoogle Scholar
  54. 54.
    Fearon ER, Hamilton SR, Vogelstein B. Clonal analysis of human colorectal tumors. Science 1987; 238: 193–7.PubMedGoogle Scholar
  55. 55.
    Fessler L, Duncan K, Tryggvason K. Identification of the procollagen IV cleavage products produced by specific tumor collagenase. J Biol Chem 1984; 259: 9783–9.PubMedGoogle Scholar
  56. 56.
    Fidler IJ. The Ernst W. Bertner Memorial Award Lecture: The evolution of biological heterogeneity in metastatic neoplasms. In: Nicolson GL, Milas L, eds. Cancer Invasion and Metastasis: Biologic and Therapeutic Aspects. New York: Raven Press, 1984: 5–26.Google Scholar
  57. 57.
    Fidler IJ. Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125I-5-iodo-2’-deoxyuridine. J Natl Cancer Inst 1970; 45: 773–82.PubMedGoogle Scholar
  58. 58.
    Fidler IJ. Special lecture: Critical factors in the biology of human cancer metastasis: Twenty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res 1990; 50: 6130–8.PubMedGoogle Scholar
  59. 59.
    Fidler IJ. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res 1978; 38: 2651–60.PubMedGoogle Scholar
  60. 60.
    Fidler IJ, Balch CM. The biology of cancer metastasis and implications for therapy. Curr Probl Surg 1987; 24: 129–209.PubMedGoogle Scholar
  61. 61.
    Fidler IJ, Berendt MJ. The biological diversity of malignant neoplasms. In: Mihich E, ed. Biological Responses in Cancer, vol. 1. New York: Plenum, 1982: 269–99.Google Scholar
  62. 62.
    Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994; 79: 185–8.PubMedGoogle Scholar
  63. 63.
    Fidler IJ, Gersten DM, Budman MB. Characterization in vivo and in vitro of tumor cells selected for resistance to syngeneic lymphocyte-mediated cytotoxicity. Cancer Res 1976; 36: 3160–5.PubMedGoogle Scholar
  64. 64.
    Fidler IJ, Hart IR. Biological diversity in metastatic neoplasms: origins and implications. Science 1982; 217: 998–1003.PubMedGoogle Scholar
  65. 65.
    Fidler IJ, Hart IR. The origin of metastatic heterogeneity in tumors. Eur J Cancer 1981; 17: 487–94.PubMedGoogle Scholar
  66. 66.
    Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977; 197: 893–5.PubMedGoogle Scholar
  67. 67.
    Fidler IJ, Poste G. The cellular heterogeneity of malignant neoplasms: implications for adjuvant chemotherapy. Semin Oncol 1985; 12: 207–22.PubMedGoogle Scholar
  68. 68.
    Fidler IJ, Radinsky R. Genetic control of cancer metastasis (editorial). J Natl Cancer Inst 1990; 82: 166–8.PubMedGoogle Scholar
  69. 69.
    Fidler IJ, Talmadge JE. The origin and progression of cancer metastases. In: Bishop JM, Rowley JD, Greaves M, eds. Genes and Cancer. New York: Liss, 1984: 239–51.Google Scholar
  70. 70.
    Fidler IJ, Wilmanns C, Staroselsky A, Radinsky R, Dong Z, Fan D. Modulation of tumor cell response to chemotherapy by the organ environment. Cancer Metastasis Rev 1994; 13: 209–22.PubMedGoogle Scholar
  71. 71.
    Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987; 84: 265–9.PubMedGoogle Scholar
  72. 72.
    Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes Memorial Award Lecture. Cancer Res 1986; 46: 467–73.PubMedGoogle Scholar
  73. 73.
    Folkman J. The role of angiogenesis in tumor growths. Semin Cancer Biol 1992; 3: 65–7.PubMedGoogle Scholar
  74. 74.
    Folkman J. What is the evidence that tumors are angiogenesis-dependent? J Natl Cancer Inst 1990; 82: 4–6.PubMedGoogle Scholar
  75. 75.
    Folkman J, Cotran R. Relation of vascular proliferation to tumor growth. Int Rev Exp Pathol 1976; 16: 207–48.PubMedGoogle Scholar
  76. 76.
    Folkman J, Klagsburn M. Angiogenic factors. Science 1987; 235: 444–7.Google Scholar
  77. 77.
    Fossa SD, De Garis ST, Heoer MS et al. Recombinant interferon-a-2a with or without vinblastine in metastatic renal cell carcinoma. Cancer 1986; 57: 1700–4.PubMedGoogle Scholar
  78. 78.
    Foulds L. The experimental study of tumor progression. A review. Cancer Res 1954; 14: 327–39.PubMedGoogle Scholar
  79. 79.
    Foulds L. The histologic analysis of mammary tumors of mice. I. Scope of investigations and general principles of analysis. J Natl Cancer Inst 1956; 17: 701–12.PubMedGoogle Scholar
  80. 80.
    Foulds L. The histologic analysis of mammary tumors of mice. II. The histology of responsiveness and progression. The origins of tumors. J Natl Cancer Inst 1956; 17: 713–54.Google Scholar
  81. 81.
    Foulds L. The histologic analysis of mammary tumors of mice. III. Organoid tumors. J Natl Cancer Inst 1956; 17: 755–82.Google Scholar
  82. 82.
    Foulds L. The histologic analysis of mammary tumors of mice. IV. Secretion. J Natl Cancer Inst 1956; 17: 783–802.Google Scholar
  83. 83.
    Friedman E, Sakaguchio K, Bale AE et al. Clonality of parathyroid tumors in familial multiple endocrine neoplasia type I. N Engl J Med 1989; 321: 213–18.PubMedGoogle Scholar
  84. 84.
    Fry DW, Kraker AJ, McMichael A et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994; 265: 1093–5.PubMedGoogle Scholar
  85. 85.
    Garnick MB, Reich SD, Maxwell B, Coval-Goldsmith S, Richie JP, Rudnick SA. Phase I/II study of recombinant interferon-y in advanced renal cell carcinoma. J Urol 1988; 139: 251–5.PubMedGoogle Scholar
  86. 86.
    Giavazzi R, Campbell DE, Jessup JM, Cleary KR, Fidler IJ. Metastatic behavior of tumor cells from primary and metastatic human colorectal carcinomas implanted into different sites in nude mice. Cancer Res 1986; 46: 1928–33.PubMedGoogle Scholar
  87. 87.
    Giavazzi R, Jessup JM, Campbell DE, Walker SM, Fidler IJ. Experimental nude mouse model of human colorectal cancer liver metastases. J Natl Cancer Inst 1986; 77: 1303–8.PubMedGoogle Scholar
  88. 88.
    Glisson B, Gupta R, Hodges R, Ross W. Cross-resistance to intercalating agents in an epipodophyllotoxin-resistant Chinese hamster ovary cell line: evidence for a common intracellular target. Cancer Res 1986; 46: 1931–41.Google Scholar
  89. 89.
    Gohji K, Fidler IJ, Tsan R et al. Human recombinant interferons-beta and -gamma decrease gelatinase production and invasion by human KG-2 renal carcinoma cells. Int J Cancer 1994; 58: 380–4.PubMedGoogle Scholar
  90. 90.
    Gohji K, Nakajima M, Dinney CPN et al. The importance of orthotopic implantation to the isolation and biological characterization of a metastatic human clear cell renal carcinoma in nude mice. Int J Oncol 1993; 2: 23–32.PubMedGoogle Scholar
  91. 91.
    Goldberg GI, Marmer BL, Grant GA, Eisen AZ, Wilhelm S, He CS. Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteinases designated TIMP-2. Proc Natl Acad Sci USA 1989; 86: 8207–11.PubMedGoogle Scholar
  92. 92.
    Goodland R, Wilson T, Lenton W, Gregory H, McCullagh K, Wright N. Intravenous but not intragastric urogastroneEGF is trophic to the intestine of parenterally fed rats. Gut 1987; 28: 573–82.Google Scholar
  93. 93.
    Gordon PB, Choi HU, Conn G et al. Extracellular matrix heparan sulfate proteoglycans modulate the mitogenic capacity of acidic fibroblast growth factor. J Cell Physiol 1988; 140: 584–92.Google Scholar
  94. 94.
    Gospodarowicz D, Greensburg G, Birdwell CR. Determination of cellular shape by the extracellular matrix and its correlation with the control of cellular growth. Cancer Res 1978; 38: 4155–71.PubMedGoogle Scholar
  95. 95.
    Gottesman MM, Pastan I. The multidrug transporter, a double-edged sword. J Biol Chem 1988; 263: 12163–6.PubMedGoogle Scholar
  96. 96.
    Gros P, Raymond M, Bell J, Housman D. Cloning and characterization of a second member of the mouse mdr gene family. Mol Cell Biol 1988; 8: 2770–8.PubMedCentralPubMedGoogle Scholar
  97. 97.
    Gross ME, Zorbas MA, Daniels YJ et al. Cellular growth response to epidermal growth factor in colon carcinoma cells with an amplified epidermal growth factor receptor derived from a familial adenomatous polyposis patient. Cancer Res 1991; 51: 1452–9.PubMedGoogle Scholar
  98. 98.
    Grupposo PA, Mead JE, Fausto N. Transforming growth factor receptors in liver regeneration following partial hepatectomy in the rat. Cancer Res 1990; 50: 1464–9.Google Scholar
  99. 99.
    Gullick WJ, Marsden JJ, Whittle N, Ward B, Bobrow L, Waterfield MD. Expression of epidermal growth factor receptors on human cervical, ovarian, and vulvar carcinomas. Cancer Res 1986; 46: 285–92.PubMedGoogle Scholar
  100. 100.
    Gutman M, Singh RK, Price JE, Fan D, Fidler IJ. Accelerated growth of human colon cancer cells in nude mice undergoing liver regeneration. Invasion Metastasis (In press).Google Scholar
  101. 101.
    Gutterman JU. Review: Cytokine therapeutics: lessons from interferon-a. Proc Natl Acad Sci USA 1994; 91: 1198–205.PubMedGoogle Scholar
  102. 102.
    Hamada H, Okochi E, Oh-hara T, Tsuruo T. Purification of the Mr 22,000 calcium-binding protein (sorcin)associated with multidrug resistance and its detection with monoclonal antibodies. Cancer Res 1988; 48: 3173–8.PubMedGoogle Scholar
  103. 103.
    Hanna N, Fidler IJ. The role of natural killer cells in the destruction of circulating tumor emboli. J Natl Cancer Inst 1980; 65: 801–9.PubMedGoogle Scholar
  104. 104.
    Harris AL, Neal DE. Epidermal growth factor and its receptor in human cancer. In: Sluyser M, ed. Growth Factors and Oncogenes in Breast Cancer. Chichester, UK: Ellis Horwood, 1987: 60–90.Google Scholar
  105. 105.
    Hart IR. “Seed and soil’’ revisited: mechanisms of site-specific metastasis. Cancer Metastasis Rev 1982; 1: 5–17.Google Scholar
  106. 106.
    Hart IR, Goode NT, Wilson RE. Molecular aspects of the metastatic cascade. Biochim Biophys Acta 1989; 989: 65–84.PubMedGoogle Scholar
  107. 107.
    Hay ED. Cell-matrix interaction in the embryo: cell shape, cell surface, and their role in differentiation. In: Trelstad RL, ed. The Role of Extracellular Matrix in Development. New York: Liss, 1984: 1–31.Google Scholar
  108. 108.
    Hayashi N, Cunha GR, Wong YC. Influence of male genital tract mesenchymes on differentiation of Dunning prostatic adenocarcinoma. Cancer Res 1990; 50: 4747–54.PubMedGoogle Scholar
  109. 109.
    Henn W, Blin N, Zang K. Polysomy of chromosome 7 is correlated with overexpression of the erbB oncogene in human glioblastoma cell lines. Hum Genet 1986; 74: 104–6.PubMedGoogle Scholar
  110. 110.
    Heppner GH. Tumor heterogeneity. Cancer Res 1984; 44: 2259–65.PubMedGoogle Scholar
  111. 111.
    Hirata Y, Moore GW, Bertagna C, Orth DN. Plasma concentration of immunoreactive human epidermal growthGoogle Scholar
  112. factor (urogastrone) in man. J Clin Endocrinol Metab 1980; 40: 440–4.Google Scholar
  113. 112.
    Hirata Y, Orth DN. Epidermal growth factor (urogastrone) in human tissues. J Clin Endocrinol Metab 1979; 48: 667.PubMedGoogle Scholar
  114. 113.
    Hori A, Sasada R, Matsutani E et al. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res 1991; 51: 6189–94.Google Scholar
  115. 114.
    Hsu SIH, Lothstein L, Horwitz SB. Differential over-expression of three mdr gene family members in multidrug resistant J774.2 cells. Evidence that distinct P-glycoprotein precursors are encoded by unique mdr genes. J Biol Chem 1989; 246: 12053–62.Google Scholar
  116. 115.
    Hu F, Wang RY, Hsu TC. Clonal origin of metastasis in B16 murine melanoma: a cytogenetic study. J Natl Cancer Inst 1987; 78: 155–63.PubMedGoogle Scholar
  117. 116.
    Hujanen ES, Turpeenniemi-Hujanen T. Recombinant interferon alpha and gamma modulate the invasive potential of human melanoma in vitro. Int J Cancer 1991; 47: 576–81.PubMedGoogle Scholar
  118. 117.
    Humphries MJ, Olden K, Yamada KM. A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science 1986; 233: 467–70.PubMedGoogle Scholar
  119. 118.
    Iwamoto Y, Robey FA, Graf J et al. YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation. Science 1987; 238: 1131–4.Google Scholar
  120. 119.
    Jain RK. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst 1989; 81: 570–6.PubMedGoogle Scholar
  121. 120.
    Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev 1987; 6: 559–93.PubMedGoogle Scholar
  122. 121.
    Kanamaru H, Kakehi Y, Yoshida O, Nakanishi S, Pastan I, Gottesman MM. MDR1 RNA levels in human renal cell carcinomas: correlation with grade and prediction of reversal of doxorubicin resistance by quinidine in tumor explants. J Natl Cancer Inst 1989; 81: 844–9.PubMedGoogle Scholar
  123. 122.
    Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science (Washington DC) 1983; 221: 1285–8.Google Scholar
  124. 123.
    Kashles O, Yarden Y, Fischer R, Ullrich A, Schlessinger J. A dominant negative mutation suppresses the function of normal epidermal growth factor receptors by heterodimerization. Mol Cell Biol 1991; 11: 1454–63.PubMedCentralPubMedGoogle Scholar
  125. 124.
    Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH, Mendelsohn J. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor antibody. Proc Natl Acad Sci USA 1983; 80: 1337–41.PubMedGoogle Scholar
  126. 125.
    Kedinger M, Haffen K, Simon-Assmann P. Intestinal tissue and cell cultures. Differentiation 1986; 36: 71–85.Google Scholar
  127. 126.
    Kedinger M, Simon-Assman P, Alexandre E, Haffen K. Importance of a fibroblastic support for in vitro differentiation of intestinal endodermal cells and for their response to glucocorticoids. Cell Differentiation 1987; 20: 171–82.PubMedGoogle Scholar
  128. 127.
    Kemeny N. Role of chemotherapy in the treatment of colorectal carcinoma. Semin Surg Oncol 1987; 3: 190–214.PubMedGoogle Scholar
  129. 128.
    Kerbel RS. Growth dominance of metastatic cancer cell: cellular and molecular aspects. Adv Cancer Res 1990; 55: 87–132.PubMedGoogle Scholar
  130. 129.
    Kern SE, Fearon ER, Tersmette KWF et al. Allelic loss in colorectal carcinoma. J Am Med Assoc 1989; 261: 3099–103.Google Scholar
  131. 130.
    Kerr LD, Olashaw NE, Matrisian LM. Transforming growth factor beta 1 and cAMP inhibit transcription of epidermal growth factor and oncogene-induced transin RNA. J Biol Chem 1988; 263: 16999–7005.PubMedGoogle Scholar
  132. 131.
    Keski-Oja J, Blasi F, Leof EB, Moses HL. Regulation of the synthesis and activity of urokinase plasminogen activator in A549 human lung carcinoma cells by transforming growth factor-beta. J Cell Biol 1988; 106: 451–9.PubMedGoogle Scholar
  133. 132.
    Khazaie K, Schirrmacher V, Lichtner RB. EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev 1993; 12: 255–74.PubMedGoogle Scholar
  134. 133.
    Khokha R, Denhardt DT. Matrix metalloproteinases and tissue inhibitor of metalloproteinases: a review of their role in tumorigenesis and tissue invasion. Invasion Metastasis 1989; 9: 391–405.PubMedGoogle Scholar
  135. 134.
    Kim KJ, Olson K, French T, Vallee B, Fett J. A monoclonal antibody to human angiogenin suppresses tumor growth in athymic mice. Cancer Res 1994; 54: 4576–9.Google Scholar
  136. 135.
    Kinney P, Triozzi P, Young D et al. Phase II trial of interferon-ß-serine in metastatic renal cell carcinoma. J Clin Oncol 1990; 8: 881–5.PubMedGoogle Scholar
  137. 136.
    Klein G, Klein E. Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host-versus-tumor evolution. Proc Natl Acad Sci USA 1977; 74: 2121–5.PubMedGoogle Scholar
  138. 137.
    Khokha R, Waterhouse P, Yagel S et al. Antisense RNA-induced reduction in murine TIMP levels confers oncogeni-city on Swiss 3T3 cells. Science 1989; 243: 947–50.PubMedGoogle Scholar
  139. 138.
    Knudson W, Biswas C, Toole BP. Interactions between human tumor cells and fibroblasts stimulate hyaluronate synthesis. Proc Natl Acad Sci USA 1984; 81: 6767–71.PubMedGoogle Scholar
  140. 139.
    Koch G, Smith M, Twentyman P, Wright K. Identification of a novel calcium-binding protein (CP22) in multidrug-resistant murine and hamster cells. FEBS Lett 1986; 195: 275–9.PubMedGoogle Scholar
  141. 140.
    Koprowski H, Herlyn M, Balaban G, Parmiter A, Ross A, Nowell P. Expression of the receptor for epidermal growth factor correlates with increased dosage of chromosome 7 in malignant melanoma. Somatic Cell Mol Genet 1985; 11: 297–302.Google Scholar
  142. 141.
    Korc M, Meltzer P, Trent J. Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer. Proc Natl Acad Sci USA 1986; 83: 5141–4.PubMedGoogle Scholar
  143. 142.
    Korczak B, Robson IB, Lamarche C, Bernstein A, Kerbel RS. Genetic tagging of tumor cells with retrovirus vectors: clonal analysis of tumor growth and metastasis in vivo. Mol Cell Biol 1988; 8: 3143–9.PubMedCentralPubMedGoogle Scholar
  144. 143.
    Kozlowski JM, Fidler IJ, Campbell D, Xu Z, Kaighn ME, Hart IR. Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res 1984; 44: 3522–9.PubMedGoogle Scholar
  145. 144.
    Kozlowski JM, Hart IR, Fidler IJ, Hanna N. A human melanoma line heterogeneous with respect to metastatic capacity in athymic nude mice. J Natl Cancer Inst 1984; 72: 913–17.PubMedGoogle Scholar
  146. 145.
    Kramer RH, Gonzalez R, Nicolson GL. Metastatic tumor cells adhere preferentially to the extracellular matrix underlying vascular endothelial cells. Int J Cancer 1980; 26: 639–45.PubMedGoogle Scholar
  147. 146.
    Krigel RL, Padavic-Shaller KA, Rudolph AR, Konrad M, Bradley EC, Comis RL. Renal cell carcinoma: treatment with recombinant interleukin-2 plus 0-interferon. J Clin Oncol 1990; 8: 460–7.PubMedGoogle Scholar
  148. 147.
    Leith JT, Dexter DL. Mammalian Tumor Cell Heterogenicity. Boca Raton, FL: CRC Press, 1986.Google Scholar
  149. 148.
    Levy A, Cioce V, Sobel ME et al. Increased expression of the 72 kDa type IV collagenase in human colonic adenocarcinoma. Cancer Res 1991; 51: 439–44.PubMedGoogle Scholar
  150. 149.
    Libermann TA, Nusbaum HR, Razon N et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary brain tumours of glial origin. Nature (London) 1985; 313: 144–7.Google Scholar
  151. 150.
    Liotta LA. Tumor invasion and metastases–role of the extracellular matrix: Rhoads Memorial Award Lecture. Cancer Res 1986; 46: 1–7.Google Scholar
  152. 151.
    Liotta LA, Thorgeirsson UP, Garbisa S. Role of collage-nases in tumor cell invasion. Cancer Metastasis Rev 1982; 1: 277–88.PubMedGoogle Scholar
  153. 152.
    Liotta LA, Tryggvason K, Garbissa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284: 67–8.PubMedGoogle Scholar
  154. 153.
    Lofts FJ, Hurst HC, Sterberg MJE, Gullick WJ. Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro and in vivo. Oncogene 1993; 8: 2813–20.PubMedGoogle Scholar
  155. 154.
    Long L, Nip J, Brodt P. Paracrine growth stimulation by hepatocyte-derived insulin-like growth factor-1: a regulatory mechanism for carcinoma cells metastatic to the liver. Cancer Res 1994; 54: 3732–7.PubMedGoogle Scholar
  156. 155.
    Luria SE, Delbruck M. Mutations of bacteria from virus sensitivity to virus resistance. Genetics 1943; 28: 491–511.PubMedGoogle Scholar
  157. 156.
    Malden L, Novak U, Burgess A. Expression of transforming growth factor alpha messenger RNA in normal and neo-plastic gastrointestinal tract. Int J Cancer 1989; 43: 380–4.PubMedGoogle Scholar
  158. 157.
    Mantovani A, Tagliabue A, Dean JH, Jerrells TR, Herber-man RB. Cytolytic activity of circulating human monocytes on transformed and untransformed human fibroblast. Int J Cancer 1979; 23: 28–31.PubMedGoogle Scholar
  159. 158.
    Markowitz SD, Molkentin K, Gerbic C, Jackson J, Stellato T, Willson JKV. Growth stimulation by coexpression of transforming growth factor-a and epidermal growth factor receptor in normal and adenomatous human colon epithelium. J Clin Invest 1990; 86: 356–62.PubMedCentralPubMedGoogle Scholar
  160. 159.
    Matrisian LM. The matrix-degrading metalloproteinases. Bioessays 1992; 14: 455–63.PubMedGoogle Scholar
  161. 160.
    McDonnell S, Matrisian LM. Stromelysin in tumor progression and metastasis. Cancer Metastatis Rev 1990; 9: 305–319.Google Scholar
  162. 161.
    McLemore TL, Liu MC, Blacker PC et al. Novel intrapulmonary model for orthotopic propagation of human lung cancers in athymic nude mice. Cancer Res 1987; 47: 5132–40.PubMedGoogle Scholar
  163. 162.
    Mead JE, Fausto N. Transforming growth factor a may be a physiological regulator of liver regeneration by means of an autocrine mechanism. Proc Natl Acad Sci USA 1989; 86: 1558–62.PubMedGoogle Scholar
  164. 163.
    Mendelsohn J. The epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. Semin Cancer Biol 1990; 1: 339–44.PubMedGoogle Scholar
  165. 164.
    Michalpoulos GK. Liver regeneration: molecular mechanisms of growth control. FASEB J 1990; 4: 176–87.Google Scholar
  166. 165.
    Mikkelsen RB, Lin PS, Wallach DF. Interaction of adriamycin with human red blood cells: a biochemical and morphological study. J Mol Med 1977; 2: 33–40.Google Scholar
  167. 166.
    Miller FR, McEachern D, Miller BE. Growth regulation of mammary tumor cells in collagen gel cultures by diffusible factors produced by normal mammary gland epithelium and stromal fibroblasts. Cancer Res 1989; 49: 6091–7.PubMedGoogle Scholar
  168. 167.
    Mizoguchi T, Yamada K, Furukawa T et al. Expression of the mdr1 gene in human gastric antral carcinomas. J Natl Cancer Inst 1990; 82: 1679–83.PubMedGoogle Scholar
  169. 168.
    Modjtahedi H, Dean C. The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer (review). Int J Oncol 1994; 4: 277–96.PubMedGoogle Scholar
  170. 169.
    Morikawa K, Walker SM, Jessup JM, Fidler IJ. In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice. Cancer Res 1988; 48: 1943–8.PubMedGoogle Scholar
  171. 170.
    Morikawa K, Walker SM, Nakajima M, Pathak S, Jessup JM, Fidler IJ. Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res 1988; 48: 6863–71.PubMedGoogle Scholar
  172. 171.
    Moscatelli D, Rifkin DB. Membrane and matrix localization of proteinases: a common theme in tumor cell invasion and angiogenesis. Biochim Biophys Acta 1988; 948: 67–85.PubMedGoogle Scholar
  173. 172.
    Moscow JA, Cowan KH. Multidrug resistance. J Natl Cancer Inst 1988; 80: 14–20.PubMedGoogle Scholar
  174. 173.
    Moulder JE, Rockwell S. Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev 1987; 5: 313–41.PubMedGoogle Scholar
  175. 174.
    Mukaida H, Hirabayashi N, Hirai T, Iwata T, Saeki S, Toge T. Significance of freshly cultured fibroblasts from different tissues in promoting cancer cell growth. Int J Cancer 1991; 48: 423–7.PubMedGoogle Scholar
  176. 175.
    Muleris M, Salmon RJ, Dutrillaux B. Chromosomal study demonstrating the clonal evolution and metastatic origin of a metachronous colorectal carcinoma. Int J Cancer 1986; 38: 167–72.PubMedGoogle Scholar
  177. 176.
    Murphree SA, Cunningham LS, Hwang KM, Sartorelli AC. Effects of adriamycin on surface properties of sarcoma 180 ascites cells. Biochem Pharmacol 1976; 25: 1227–31.PubMedGoogle Scholar
  178. 177.
    Mydlo JH, Heston WD, Fair WR. Characterization of a heparin-binding growth factor from adenocarcinoma of the kidney. J Urol 1988; 140: 1575–9.PubMedGoogle Scholar
  179. 178.
    Nair S, Samy TS, Krishan A. Calcium, calmodulin, and protein content of adriamycin-resistant and -sensitive murine leukemia cells. Cancer Res 1986; 46: 229–32.PubMedGoogle Scholar
  180. 179.
    Naito S, Giavazzi R, Fidler IJ. Correlation between the in vitro interaction of tumor cells with an organ environment and metastatic behavior in vivo. Invasion Metastasis 1987; 7: 16–29PubMedGoogle Scholar
  181. 180.
    Naito S, von Eschenbach AC, Giavazzi R, Fidler IJ. Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res 1986; 46: 4109–15.PubMedGoogle Scholar
  182. 181.
    Naito S, Walker SM, Fidler IJ. In vivo selection of human renal carcinoma cells with high metastatic potential in nude mice. Clin Exp Metastasis 1989; 7: 381–9.PubMedGoogle Scholar
  183. 182.
    Naito S, Walker SM, von Eschenbach AC, Fidler IJ. Evidence for metastatic heterogeneity of a human renal cell carcinoma. Anticancer Res 1988; 8: 1163–8.PubMedGoogle Scholar
  184. 183.
    Nakajima M, Morikawa K, Fabra A, Bucana CD, Fidler IJ. Influence of organ environment on extracellular matrix degradative activity and metastasis of human colon carcinoma cells. J Natl Cancer Inst 1990; 82: 1890–8.PubMedGoogle Scholar
  185. 184.
    Nanus DM, Schmitz-Drager BI, Motzer RJ et al. Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst 1994; 85: 1597–9.Google Scholar
  186. 185.
    Neal DE, Marsh C, Bennet MK et al. Epidermal growth factor receptor in human bladder cancer: comparison of invasive and superficial tumours. Lancet 1985; i: 366–8.Google Scholar
  187. 186.
    Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994; 86: 356–61.PubMedGoogle Scholar
  188. 187.
    Nicolson GL. Cancer metastasis: tumor cell and host organ properties important in metastasis to specific secondary sites. Biochim Biophys Acta 1988; 948: 175–224.PubMedGoogle Scholar
  189. 188.
    Nicolson GL. Cancer progression and growth: relationship of paracrine and autocrine growth mechanisms to organ preference of metastasis. Exp Cell Res 1993; 204: 171–80.PubMedGoogle Scholar
  190. 189.
    Nicolson GL. Generation of phenotypic diversity and progression in metastatic tumors. Cancer Metastasis Rev 1984; 3: 25–42.PubMedGoogle Scholar
  191. 190.
    Nicolson GL. Metastatic tumor cell interactions with endothelium, basement membrane, and tissue. Curr Opin Cell Biol 1989; 1: 1009–19.PubMedGoogle Scholar
  192. 191.
    Noji S, Tashiro K, Koyama E et al. Expression of hepatocyte growth factor gene in endothelial and Kupffer cells of damaged rat livers, as revealed by in situ hybridization. Biochem Biophys Res Commun 1990; 173: 42–7.PubMedGoogle Scholar
  193. 192.
    Nowell PC. Chromosomal and molecular clues to tumor progression. Semin Oncol 1989; 16: 116–27.PubMedGoogle Scholar
  194. 193.
    Nowell PC. The clonal evolution of tumor cell populations: acquired genetic lability permits stepwise selection of variant sublines and underlies tumor progression. Science 1976; 194: 23–8.PubMedGoogle Scholar
  195. 194.
    Nowell PC. Mechanisms of tumor progression. Cancer Res 1986; 46: 2203–7.PubMedGoogle Scholar
  196. 195.
    O’Brian CA, Fan D, Ward NE, Seid C, Fidler IJ. Level of protein kinase C activity correlates directly with resistance to adriamycin in murine fibrosarcoma cells. FEBS Lett 1989; 246: 78–82.PubMedGoogle Scholar
  197. 196.
    O’Brian CA, Ward NE. Biology of the protein kinase C family. Cancer Metastasis Rev 1989; 8: 199–214.PubMedGoogle Scholar
  198. 197.
    Olsson L. Phenotypic diversity of malignant cell populations: molecular mechanisms and biological significance. Cancer Res 1986; 3: 91–114.Google Scholar
  199. 198.
    Ootsuyama A, Tanaka K, Tanooka H. Evidence by cellular mosaicism for monoclonal metastasis of spontaneous mouse mammary tumors. J Natl Cancer Inst 1987; 78: 1223–7.PubMedGoogle Scholar
  200. 199.
    Ostrowski LE, Finch J, Krieg P et al. Expression pattern of a gene for a secreted metalloproteinase during late stage of tumor progression. Mol Carcinog 1988; 1: 13–19.PubMedGoogle Scholar
  201. 200.
    Overall CM, Wrana JL, Sodek J. Independent regulation of collagenase, 72-kDa progelatinase, and metalloendoproteinase inhibitor expression in human fibroblasts by transforming growth factor-beta. J Biol Chem 1989; 25: 1860–9.Google Scholar
  202. 201.
    Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 1: 571–3.Google Scholar
  203. 202.
    Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV, Willingham MC. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 1988; 85: 4486–90.PubMedGoogle Scholar
  204. 203.
    Phillips PC, Levow C, Catterall M, Colvin OM, Pastan I, Brem H. Transforming growth factor-a-Pseudomonas exotoxin fusion protein (TGF-a-PE38)treatment of subcutaneous and intracranial human glioma and medulloblastoma xenografts in athymic mice. Cancer Res 1994; 54: 1008–15.PubMedGoogle Scholar
  205. 204.
    Pigram WJ, Fuller W, Hamilton LDH. Stereochemistry of intercalation: interaction of daunomycin with DNA. Nature 1971235: 17–19Google Scholar
  206. 205.
    Plowman GD, Green JM, McDonald VL et al. The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumor-inhibitory activity. Mol Cell Biol 1981; 10: 1969–81.Google Scholar
  207. 206.
    Poste G. Experimental systems for analysis of the malignant phenotype. Cancer Metastasis Rev 1982; 1: 141–99.PubMedGoogle Scholar
  208. 207.
    Poste G, Tzeng J, Doll J, Greig R, Rieman D, Zeidman I. Evolution of tumor cell heterogeneity during progressive growth of individual lung metastases. Proc Natl Acad Sci USA 1982; 79: 6574–8.PubMedGoogle Scholar
  209. 208.
    Postlethwaite AE, Lachman LB, Mainardi CL, Kang AH. Interleukin 1 stimulation of collagenase production by cultured fibroblasts. J Exp Med 1983; 157: 801–6.PubMedGoogle Scholar
  210. 209.
    Pratesi G, Manzotti C, Tortoreto M, Audisio RA, Zunino F. Differential efficacy of flavone acetic acid against liver versus lung metastases in a human tumour xenograft. Br J Cancer 1991; 663: 71–4.Google Scholar
  211. 210.
    Prehn RT. Tumor progression and homeostasis. Adv Cancer Res 1976; 23: 203–36.PubMedGoogle Scholar
  212. 211.
    Presta M, Maier JA, Ragnotti GJ. The mitogenic signaling pathway but not the plasminogen activator-inducing pathway of basic fibroblast growth factor is mediated through protein kinase C in fetal bovine aortic endothelial cells. Cell Biol 1989; 109: 1877–84.Google Scholar
  213. 212.
    Price JE, Aukerman SL, Fidler IJ. Evidence that the process of murine melanoma metastasis is sequential and selective and contains stochastic elements. Cancer Res 1986; 46: 5172–8.PubMedGoogle Scholar
  214. 213.
    Price JE, Daniels LM, Campbell DE, Giavazzi R. Organ distribution of experimental metastases of a human colorectal carcinoma injected in nude mice. Clin Exp Metastasis 1989; 7: 55–68.PubMedGoogle Scholar
  215. 214.
    Radinsky R. Growth factors and their receptors in metastasis. Semin Cancer Biol 1991; 2: 169–77.PubMedGoogle Scholar
  216. 215.
    Radinsky R. Paracrine growth regulation of human colon carcinoma organ-specific metastases. Cancer Metastasis Rev 1993; 12: 345–61.PubMedGoogle Scholar
  217. 216.
    Radinsky R, Beltran PJ, Tsan R, Zhang R, Cone RD, Fidler IJ. Transcriptional induction of the melanocyte-stimulating hormone receptor in brain metastases of murine K-1735 melanoma. Cancer Res 1995; 55: 141–8.PubMedGoogle Scholar
  218. 217.
    Radinsky R, Bucana CD, Ellis LE et al. A rapid colori-metric in situ messenger RNA hybridization technique for analysis of epidermal growth factor receptor in paraffin-embedded surgical specimens of human colon carcinomas. Cancer Res 1993; 53: 937–43.PubMedGoogle Scholar
  219. 218.
    Radinsky R, Fidler IJ, Price JE et al. Terminal differentiation and apoptosis in experimental lung metastases of human osteogenic sarcoma cells by wild type p53. Oncogene 1994; 9: 1877–83.PubMedGoogle Scholar
  220. 219.
    Radinsky R, Risin S, Fan D et al. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1995; 1: 19–31.PubMedGoogle Scholar
  221. 220.
    Raymond M, Rose E, Housman DE, Gros P. Physical mapping, amplification, and overexpression of the mouse mdr gene family in multidrug-resistant cells. Mol Cell Biol 1990; 10: 1642–51.PubMedCentralPubMedGoogle Scholar
  222. 221.
    Real FX, Oettgen HF, Krown SE. Kaposi’s sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte interferon. J Clin Oncol 1986; 4: 544–51.PubMedGoogle Scholar
  223. 222.
    Redemann N, Holzmann B, von Ruden T, Wagner EF, Schlessinger J, Ullrich A. Antioncogenic activity of signalling defective epidermal growth factor receptor mutants. Mol Cell Biol 1992; 12: 491–8.PubMedCentralPubMedGoogle Scholar
  224. 223.
    Reid LM, Abreu SL, Montgomery K. Extracellular matrix and hormonal regulation of synthesis and abundance of messenger RNAs in cultured liver cells. In: Arias IM, Jakoby WB, Popper H, Schachter D, Shafritz DA, eds. The Liver: Biology and Pathobiology, 2nd edn. New York: Raven Press, 1988: 717–37.Google Scholar
  225. 224.
    Rinehart JJ, Young D, LaForge J, Colburn D, Neidhart JA. Phase I/II trial of interferon-ß-serine in patients with renal cell carcinoma: immunological and biological effects. Cancer Res 1987; 47: 2481–5.PubMedGoogle Scholar
  226. 225.
    Roberts AB, Sporn MB, Assoian RK et al. Transforming growth factor type B: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986; 83: 4167–71.PubMedGoogle Scholar
  227. 226.
    Roberts AB, Thompson NL, Heine U, Flanders C, Sporn MB. Transforming growth factor ß: possible roles in carcinogenesis. Br J Cancer 1988; 57: 594–600.PubMedCentralPubMedGoogle Scholar
  228. 227.
    Rothenberg M, Ling V. Multidrug resistance: molecular biology and clinical relevance. J Natl Cancer Inst 1989; 81: 907–10.PubMedGoogle Scholar
  229. 228.
    Russell AH, Tong D, Dawson LE, Wisbeck W. Adenocarcinoma of the proximal colon: sites of initial dissemination and patterns of recurrence following surgery alone. Cancer 1984; 53: 360–7.PubMedGoogle Scholar
  230. 229.
    Saiki I, Naito S, Yoneda J, Azuma I, Price JE, FidlerIJ. Characterization of the invasive and metastatic phenotype in human renal cell carcinoma. Clin Exp Metastasis 1991; 9: 551–66.PubMedGoogle Scholar
  231. 230.
    Sainsbury JRC, Sherbert GV, Farndon JR, Harris AL. Epidermal growth factor receptors and oestrogen receptors in human breast cancer. Lancet 1986; 1: 364–6.Google Scholar
  232. 231.
    Sartorelli AC. Therapeutic attack of hypoxic cells of solid tumors: Presidential address. Cancer Res 1988; 48: 775–8.Google Scholar
  233. 232.
    Sauter G, Haley T, Chew K et al. Epidermal growth factor receptor expression is associated with rapid tumor proliferation in bladder cancer. Int J Cancer 1994; 57: 508–14.PubMedGoogle Scholar
  234. 233.
    Schackert G, Fidler IJ. Development of in vivo models for studies of brain metastasis. Int J Cancer 1988; 41: 589–94.PubMedGoogle Scholar
  235. 234.
    Schackert G, Fidler IJ. Site-specific metastasis of mouse melanomas and a fibrosarcoma in the brain or the meninges of syngeneic animals. Cancer Res 1988; 48: 3478–83.PubMedGoogle Scholar
  236. 235.
    Schlaifer D, Laurent G, Chittal S et al. Immunohistochemical detection of multidrug resistance-associated P-glycoprotein in tumor and stromal cells of human cancers. Br J Cancer 1990; 62: 177–82.PubMedCentralPubMedGoogle Scholar
  237. 236.
    Schlessinger J. Allosteric regulation of the epidermal growth factor receptor kinase. J Cell Biol 1986; 103: 2067–72.PubMedGoogle Scholar
  238. 237.
    Schor SL, Schor AM. Clonal heterogeneity in fibroblast phenotype: implications for the control of epithelial-mesenchymal interactions. BioEssays 1987; 7: 200–4.PubMedGoogle Scholar
  239. 238.
    Schwarz LC, Gingras MC, Goldberg G, Greenberg AH, Wright JA. Loss of growth factor dependence and conversion of transforming growth factor-ß1 inhibition to stimulation in metastatic H-ras-transformed murine fibroblasts. Cancer Res 1988; 48: 6999–7003.PubMedGoogle Scholar
  240. 239.
    Selva E, Raden DL, Davis RJ. Mitogen-activated protein kinase stimulation by a tyrosine kinase-negative epidermal growth factor receptor. J Biol Chem 1993; 268: 2250–4.PubMedGoogle Scholar
  241. 240.
    Shafie SM, Liotta LA. Formation of metastasis by human breast carcinoma cells (MCF-7) in nude mice. Cancer Lett 1980; 11: 81–7.PubMedGoogle Scholar
  242. 241.
    Shapiro SD, Campbell EJ, Kobayashi DK, Welgus HG. Immune modulation of metalloproteinase production in human macrophages: selective suppression of interstitial collagenase and stromelysin biosynthesis by interferon-y. J Clin Invest 1990; 86: 1204–10.PubMedCentralPubMedGoogle Scholar
  243. 242.
    Shen DW, Fojo A, Chin IE et al. Human multidrug resistant cell lines: increased mdr1 expression can precede gene amplification. Science 1986; 232: 643–5.PubMedGoogle Scholar
  244. 243.
    Siegall CB, Fitzgerald DJ, Pastan I. Selective killing of tumor cells using EGF or TCGa-Pseudomonas exotoxin chimeric molecules. Semin Cancer Biol 1990; 1: 345–50.PubMedGoogle Scholar
  245. 244.
    Silverberg BS, Lubera JA. Cancer statistics, 1989. CA, 1989, 39: 3–4.PubMedGoogle Scholar
  246. 245.
    Singh RK, Bucana CD, Gutman M, Fan D, Wilson MR, Fidler IJ. Organ site-dependent expression of basic fibroblast growth factor in human renal cell carcinoma cells. Am J Pathol 1994; 145: 365–74.PubMedGoogle Scholar
  247. 246.
    Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ. Interferons alpha and beta downregulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 1995; 92: 4562–6.PubMedGoogle Scholar
  248. 247.
    Singh RK, Gutman M, Radinsky R, Bucana CD, Fidler IJ. Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res 1994; 54: 3242–7.PubMedGoogle Scholar
  249. 248.
    Slack NH, Bross JDJ. The influence of the site of metastasis on tumor growth and response to chemotherapy. Br J Cancer 1975; 32: 78–86.PubMedCentralPubMedGoogle Scholar
  250. 249.
    Sloane BF. Cathepsin B and cystatins: evidence for a role in cancer progression. Semin Cancer Biol 1990; 1: 137–52.PubMedGoogle Scholar
  251. 250.
    Smith KA, Begg AC, Denekamp J. Differences in chemosensitivity between subcutaneous and pulmonary tumors. Eur J Cancer Clin Oncol 1985; 21: 249–56.PubMedGoogle Scholar
  252. 251.
    Spremulli EN, Scott C, Campbell DE et al. Characterization of two metastatic subpopulations originating from a single human colon carcinoma. Cancer Res 1983; 43: 3828–35.PubMedGoogle Scholar
  253. 252.
    Staroselsky A, Fan D, O’Brian CA, Bucana CD, Gupta KP, Fidler IJ. Site-dependent differences in response of the UV-Google Scholar
  254. 2237.
    murine fibrosarcoma to systemic therapy with adriamycin. Cancer Res 1990; 40: 7775–80.Google Scholar
  255. 253.
    Staroselsky AN, Radinsky R, Fidler IJ, Pathak S, Chernajovsky Y, Frost P. The use of molecular genetic markers to demonstrate the effect of organ environment on clonal dominance in a human renal cell carcinoma grown in nude mice. Int J Cancer 1992; 51: 130–8.PubMedGoogle Scholar
  256. 254.
    Steiner MG, Harlow SP, Colombo E, Bauer KD. Chromosomes 8, 12, and 17 copy number in Astler-Coller stage C colon cancer in relation to proliferative activity and DNA ploidy. Cancer Res 1993; 53: 681–6.Google Scholar
  257. 255.
    Stephenson RA, Dinney CPN, Gohji K, Ordonez NG, Killion JJ, Fidler IJ. Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J Natl Cancer Inst 1992; 84: 951–7.PubMedGoogle Scholar
  258. 256.
    Stetler-Stevenson WG. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev 1990; 9: 2889–303.Google Scholar
  259. 257.
    Stetler-Stevenson WG, Krutsch HC, Wacher MP, Margulies IM, Liotta LA. The activation of human type IV collagenase proenzyme. J Biol Chem 1989; 264: 1353–6.PubMedGoogle Scholar
  260. 258.
    Stiles CD, Capone GT, Scher CD, Antoniades HN, Van Wyk JJ, Pledger WJ. Dual control of cell growth by somatomedins and platelet-derived growth factor. Proc Natl Acad Sci USA 1979; 76: 1279–83.PubMedGoogle Scholar
  261. 259.
    Sugarbaker EV. Patterns of metastasis in human malignancies. Cancer Biol Rev 1981; 2: 235–78.Google Scholar
  262. 260.
    Suzuki M, Hori K, Abe I. A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. J Natl Cancer Inst 1981; 67: 663–9.PubMedGoogle Scholar
  263. 261.
    Suzuki M, Hori M, Abe I, Sachiko S, Sato H. Functional characterization of the microcirculation in tumors. Cancer Metastasis Rev 1984; 3: 115–26.PubMedGoogle Scholar
  264. 262.
    Talmadge JE, Benedict K, Madsen J, Fidler IJ. The development of biological diversity and susceptibility to chemotherapy in cancer metastases. Cancer Res 1984; 44: 3801–5.PubMedGoogle Scholar
  265. 263.
    Talmadge JE, Myers KM, Prieur DJ, Starkey JR. Role of natural killer cells in tumor growth and metastasis: C57BL/ 6 normal and beige mice. J Natl Cancer Inst 1980; 65: 929–35.PubMedGoogle Scholar
  266. 264.
    Talmadge JE, Wolman SR, Fidler IJ. Evidence for the clonal origin of spontaneous metastases. Science 1982; 217: 361–3.PubMedGoogle Scholar
  267. 265.
    Talmadge JE, Zbar B. Clonality of pulmonary metastases from the bladder 6 subline of the B16 melanoma studied by Southern hybridization. J Natl Cancer Inst 1987; 778: 315–20.Google Scholar
  268. 266.
    Tan MH, Chu TM. Characterization of the tumorigenic and metastatic properties of a human pancreatic tumor cell line (ASPC-1)implanted orthotopically into nude mice. Tumour Biol 1985; 6: 89–98.PubMedGoogle Scholar
  269. 267.
    Tanaka H, Mori Y, Ishii H. Enhancement of metastatic capacity of fibroblast-tumor cell interaction in mice. Cancer Res 1988; 48: 1456–9.PubMedGoogle Scholar
  270. 268.
    Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 1989; 49: 4373–84.PubMedGoogle Scholar
  271. 269.
    Tarin D, Price JE, Kettlewell MGW, Souter RG, Vass ACR, Crossley B. Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res 1984; 44: 3584–92.PubMedGoogle Scholar
  272. 270.
    Teicher BA, Alvarez-Sotomayor E, Huang ZD. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 1992; 52: 6702–4.PubMedGoogle Scholar
  273. 271.
    Teicher BA, Holden SA, Al-Achi A, Herman TS. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res 1990; 50: 3339–44.PubMedGoogle Scholar
  274. 272.
    Teicher BA, Holden SA, Ara G et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other antiangiogenic agents. Int J Cancer 1994; 57: 920–5.PubMedGoogle Scholar
  275. 273.
    Teicher BA, Lazo JS, Sartorelli AC. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 1981; 41: 73–81.PubMedGoogle Scholar
  276. 274.
    Testa JE, Quigley JP. The role of urokinase-type plasminogen activator in aggressive tumor cell behavior. Cancer Metastasis Rev 1990; 9: 353–67.PubMedGoogle Scholar
  277. 275.
    Testa JE, Quigley JP. Reversal of misfortune: TIMP-2 inhibits tumor cell invasion. J Natl Cancer Inst 1991; 83: 740–2.PubMedGoogle Scholar
  278. 276.
    Thorgeirsson SS, Huber BE, Sorell S, Fojo A, Pastan I, Gottesman MM. Expression of the multidrug-resistant gene in hepatocarcinogenesis and regenerating rat liver. Science 1987; 236: 1120–2.PubMedGoogle Scholar
  279. 277.
    Tozer GM, Lewis S, Michalowski A, Aber V. The relationship between regional variations in blood flow and histology in a transplanted rat fibrosarcoma. Br J Cancer 1990; 61: 250–7.PubMedCentralPubMedGoogle Scholar
  280. 278.
    Trinks U, Buchdunger E, Furet P et al. Dianilinophtalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase. J Med Chem 1994; 37: 1015–27.PubMedGoogle Scholar
  281. 279.
    Tryggvason K, Hoyhtya M, Salo T. Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta 1987; 907: 191–217.PubMedGoogle Scholar
  282. 280.
    Tsuruo T. Mechanisms of multidrug resistance and implication for therapy. Jpn J Cancer Res 1988; 79: 285–96.PubMedGoogle Scholar
  283. 281.
    Tsuruo T, Iida H, Kawabara H, Tsukagoshi S, Sakurai Y. High calcium content of pleiotropic drug-resistant P388 and K562 leukemia and Chinese hamster ovary cells. Cancer Res 1984; 44: 5095–9.PubMedGoogle Scholar
  284. 282.
    Ullrich AL, Coussens L, Hayflick JS et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature (London) 1984; 309: 418–25.Google Scholar
  285. 283.
    van Dale P, Galand P. Effect of partial hepatectomy on experimental liver invasion by intraportally injected colon carcinoma cells in rats. Invasion Metastasis 1988; 8: 217–27.PubMedGoogle Scholar
  286. 284.
    van der Geer P, Hunter T, Lindberg RA. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 1994; 10: 251–337.PubMedGoogle Scholar
  287. 285.
    Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989; 49: 6449–65.PubMedGoogle Scholar
  288. 286.
    Vogelstein B, Fearon ER, Kern SE et al. Allelotype of colorectal carcinomas. Science 1989; 244: 207–22.PubMedGoogle Scholar
  289. 287.
    Waghorne C, Thoma M, Lagarde A, Kerbel RS, Breitman ML. Genetic evidence for progressive selection and overgrowth of primary tumors by metastatic cell subpopulations. Cancer Res 1988; 48: 6109–14.PubMedGoogle Scholar
  290. 288.
    Waldman FM, Carroll PR, Kerschmann R, Cohen MB, Field FG, Mayall BH. Centromeric copy number of chromosome 7 is strongly correlated with tumor grade and labeling index in human bladder cancer. Cancer Res 1991; 51: 3807–13.PubMedGoogle Scholar
  291. 289.
    Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143: 401–9.PubMedGoogle Scholar
  292. 290.
    Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis–correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1–8.PubMedGoogle Scholar
  293. 291.
    Weinstetin RS, Kuszak IR, Kluskens LF, Cons JS. Pglycoprotein in pathology: the multidrug resistance gene family in humans. Hum Pathol 1990; 21: 34–48.Google Scholar
  294. 292.
    Welch DR, Fabra A, Nakajima M. Transforming growth factor-beta stimulates mammary adenocarcinoma cell inva-Google Scholar
  295. sion and metastatic potential. Proc Natl Acad Sci USA 1990; 87: 7678–82.Google Scholar
  296. 293.
    Welch DR, Tomasovic SP. Implications of tumor progression on clinical oncology. Clin Exptl Metastasis 1985; 3: 151–88.Google Scholar
  297. 294.
    Wilhelm SM, Collier IE, Mar er BL et al. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collage-nase which is identical to that secreted by normal human macrophages. J Biol Chem 1989; 264: 17213–21.PubMedGoogle Scholar
  298. 295.
    Wilmanns C, Fan D, O’Brian CA et al. Modulation of doxorubicin sensitivity and level of P-glycoprotein expression in human colon carcinoma cells by ectopic and orthotopic environments in nude mice. Int J Oncol 1993; 3: 413–22.PubMedGoogle Scholar
  299. 296.
    Yunis JJ. The chromosomal basis of human neoplasia. Science 1983; 221: 227–36.PubMedGoogle Scholar
  300. 297.
    Zarrilli R, Bruni CB, Riccio A. Multiple levels of control of insulin-like growth factor gene expression. Mol Cell Endocrinol 1994; 101: R1–R14.PubMedGoogle Scholar
  301. 298.
    Zvibel I, Halay E, Reid LM. Heparin and hormonal regulation of mRNA synthesis and abundance of autocrine growth factors: relevance to clonal growth of tumors. Mol Cell Biol 1991; 11: 108–16.PubMedCentralPubMedGoogle Scholar
  302. 299.
    Zwelling LA, Michaels S, Erickson LC, Ungeleier RS, Nichols M, Kohn K. Protein-associated DNA breaks in L1210 cells treated with the DNA intercalating agents 4’- (9-acridinylamino)-methanesuflon-m-anisidide and adriamycin. Biochemistry 1981; 20: 6553–63.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2003

Authors and Affiliations

  • Robert Radinsky
  • Sharon L. Aukerman
  • Isaiah J. Fidler

There are no affiliations available

Personalised recommendations